NCI participated in the American Association for Cancer Research (AACR) Annual Meeting, held virtually on April 27 and April 28, 2020, including presenting the following research results from PREVENT and Early Phase Clinical Projects outlined below.
The PREVENT Cancer Preclinical Drug Development Program (PREVENT) is a peer-reviewed program designed to support development of the best ideas in cancer prevention using National Cancer Institute contract resources. The program is a pipeline that focuses on unmet needs in prevention that are not adequately addressed by the private sector. NCI actively partners with successful applicants to help them move their novel cancer preventive chemical or biological agents (singly or in combination) and biomarkers from the lab bench towards IND filing, proof-of principle clinical testing and registration or validation.
The Division of Cancer Prevention conducts systematic early clinical development of promising preventive agents through its Phase 0/I/II Cancer Prevention Clinical Trials Program, also known as the Consortia for Early Phase Prevention Trials. Cancer prevention drug discovery is identifying many new agents, including an increasing number of agents that intervene in specific molecular pathways thought to be critical to cancer development. Since cancer prevention studies focus on high-risk populations that do not necessarily harbor a detectable cancer, these studies require extensive biomarker analysis, investigation of the biologic effects of the cancer preventive agents on their intended molecular targets, and correlation with clinically relevant endpoints.
PREVENT-funded Project Presentations
Tuesday, April 28
10:45 AM—12:30 PM
Session Type: Virtual Minisymposium
Session Category: Prevention Research
Session Title: Prevention Research
1099—Combination of bazedoxifene and lapatinib profoundly inhibits estrogen receptor positive (ER+) and Negative (ER-) mammary tumorigenesis
Altaf Mohammed1, Shizuko Sei1, Robert H. Shoemaker1, Clinton J. Grubbs2. 1National Cancer Institute, Rockville, MD; 2Univ. of Alabama Comp. Cancer Ctr., Birmingham, AL.
1102—Model optimization and chemoprevention of IPMN driven PDAC in KPSD4 mouse model
Gaurav Kumar1, Venkateshwar Madka1, Anil Singh1, Nandini Kumar1, Nicole Stratton1, Stanley Lightfoot1, Altaf Mohammed2, Mark S. Miller2, Chinthalapally V. Rao1. 1Univ. of Oklahoma Health Sciences Ctr., Oklahoma City, OK; 2National Cancer Institute, Rockville, MD.
DCP-funded Early Phase Clinical Project Presentations
Monday, April 27
9:00 AM—6:00 PM
Session Type: Virtual Poster Session
Session Category: Clinical Trials
Session Title: Phase I Clinical Trials
CT111—Naproxen chemoprevention promotes immune activation in Lynch syndrome colorectal mucosa
Laura Ryes Uribe1, Wenhui Wu1, Ozkan Gelincik2, Prashant V. Bommi1, Alejandro Francisco-Cruz1, Luisa M. Solis1, Patrick M. Lynch1, Romana Lim3, Elena Stoffel4, Priyanka Kanth5, N. Jewel Samadder6, Maureen E. Mork1, Melissa W. Taggart1, Ginger L. Milne7, Lawrence J. Marnett7, Lana Vornik1, Diane D. Liu1, Maria Revuelta2, Kyle Chang1, Y. Nancy You1, Levy Kopelovich2, Ignacio I. Wistuba1, J. Jack Lee1, Shizuko Sei8, Robert H. Shoemaker8, Eva Szabo8, Ellen Richmond8, Asad Umar8, Marjorie Perloff8, Powell H. Brown1, Steven M. Lipkin2, Eduardo Vilar1. 1The University of Texas MD Anderson Cancer Center, Houston TX; 2Weill Cornell Medical College, New York, NY; 3Dana-Farber/Brigham and Women’s Cancer Center, Boston, MA; 4University of Michigan, Ann Arbor, MI; 5Huntsman Cancer Institute, Salt Lake City, UT; 6Mayo Clinic, Phoenix, AZ; 7Vanderbilt University School of Medicine, Nashville, TN; 8NCI Division of Cancer Prevention, Bethesda, MD.